BRIEF—TLC and 3SBio agree to collaborate in China

Taiwan Liposome Company and China’s 3SBio have announced an exclusive partnership to commercialize two liposomal products in mainland China. The products use TLC's NanoX technology platform.

The firms will work together to secure regulatory approvals in mainland China, and TLC will supply the products for 3SBio to commercialize there.

They will also collaborate to develop novel liposomal products in the therapeutic areas of osteoarthritis, pain management, ophthalmology, and oncology.

Under the terms of the deal, TLC will receive up to $25 million in upfront payments for each product, as well as regulatory and sales milestone payments, plus royalties.